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Abstract
Mutations in mitochondrial (mt) genes coding for mt-tRNAs are responsible for a range of syndromes, for which no effective
treatment is available. We recently showed that the carboxy-terminal domain (Cterm) of human mt-leucyl tRNA synthetase
rescues the pathologic phenotype associated either with the m.3243A>Gmutation in mt-tRNALeu(UUR) or with mutations in the
mt-tRNAIle, both ofwhich are aminoacylated by Class Imt-aminoacyl-tRNAsynthetases (mt-aaRSs). Herewe show, by using the
human transmitochondrial cybrid model, that the Cterm is also able to improve the phenotype caused by the m.8344A>G
mutation in mt-tRNALys, aminoacylated by a Class II aaRS. Importantly, we demonstrate that the same rescuing ability is
retained by two Cterm-derived short peptides, β30_31 and β32_33, which are effective towards both the m.8344A>G and the
m.3243A>G mutations. Furthermore, we provide in vitro evidence that these peptides bind with high affinity wild-type and
mutant human mt-tRNALeu(UUR) and mt-tRNALys, and stabilize mutant mt-tRNALeu(UUR). In conclusion, we demonstrate that
small Cterm-derived peptides can be effective tools to rescue cellular defects caused bymutations in awide range ofmt-tRNAs.
Introduction
Mitochondrial (mt) diseases are multi-system disorders due to
mutations in nuclear or mtDNA genes. Among the latter, >50%
are located in transfer RNA (tRNA) genes [(1); URL: http://www.
mitomap.org] and are responsible for awide range of clinical phe-
notypes, such as the severe Mitochondrial Encephalopathy with
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Lactic Acidosis and Stroke like Episodes (MELAS) and Myoclonic
Epilepsy with Ragged-Red Fibres (MERRF) syndromes, for which
no effective treatments are available at present (2).
Evidence provided by our group and others has shown that
overexpression of mt-aminoacyl-tRNA synthetases (mt-aaRSs)
attenuates the detrimental effects of point mutations in cognate
mt-tRNAs both in human cells (3–6) and in a yeast model (7,8).
Our group and others extended these results by showing that
class Ia human mt-leucyl-tRNA synthetase (mt-LeuRS) and mt-
valyl-tRNA synthetase (mt-ValRS) are able to rescue defects due
to pathogenic mutations in non-cognate, as well as cognate, mt-
tRNAs, in both human transmitochondrial cybrid cells (herein
named cybrids) (9,10) and yeast (11).
We further demonstrated that the rescuing activity of human
mt-LeuRS resides in a relatively small (<70 amino acids) protein
region: the carboxy-terminal domain (Cterm) (9,10). Cterm over-
expression in human cybrids rescued both relativelymild defects
caused by two different homoplasmic mutations in the non-
cognate mt-tRNAIle gene (MTTI), and severe pathological pheno-
types caused by the heteroplasmic m.3243A>G mutation in the
cognate mt-tRNALeu(UUR) gene (MTTL1) (9). The latter mutation
is the most prevalent heteroplasmic mt-tRNA mutation asso-
ciated with mt disease, leading to a wide spectrum of clinical
manifestations. These are partly determined by the level of het-
eroplasmy and include maternally inherited diabetes and deaf-
ness and the severe biochemical and clinical phenotypes
ascribed to MELAS (12,13). We showed that the Cterm is both ne-
cessary and sufficient for the entire rescuing activity. It is more
effective than the full-length enzyme on all mtDNA mutations
tested, whereas the activity of a mt-LeuRS variant deleted of
the Cterm is negligible or missing (9). We proposed that the
Cterm rescuing activity is mediated by a chaperone-like mech-
anism: the Cterm would directly interact with the mutated
mt-tRNAs and stabilize a conformation suitable to establish in-
teractions with cognate aaRS, or other molecular partners re-
quired to perform tRNA function. This hypothesis is supported
by in vitro experiments demonstrating that the Cterm directly in-
teracts with both the cognate human mt-tRNALeu(UUR), with high
affinity and stability, and with the non-cognate human mt-
tRNAIle, although with lower affinity (9).
To identify theminimal Cterm regions responsible for the res-
cue, we designed short peptides comprising the Cterm regions
that interact with tRNALeu in the available three-dimensional
(3D) structures (14,15). These peptides were named β30_31 (15
aa) and β32_33 (16 aa), since they encompass β-strands 30 and
31, and β-strands 32 and 33, respectively. Both peptides were en-
dowed with even higher rescuing activity than the full Cterm
when directed to a large panel of yeast mt-tRNAmutants (16,17).
In thework here presented, we have investigated the rescuing
ability of β30_31 and β32_33 peptides in human cybrids bearing
either the aforementioned m.3243A>G mutation in MTTL1, or
them.8344A>GMERRFmutation inmt-tRNALys (MTTK). Both pep-
tides are able to ameliorate viability and energetic proficiency of
human cells carrying either mutation and to interact in vitrowith
mutant human mt-tRNALeu(UUR) and mt-tRNALys. In the case of
the ‘cognate’ mt-tRNALeu(UUR) m.3243A>G mutant, both peptides
also restore wild-type (WT) levels of thermal stability and struc-
ture, which are strongly impaired by the mutations.
These results indicate that β30_31 and β32_33 peptides,
derived from the Cterm fragment of mt-LeuRS, are new tools to
effectively correct defective phenotypes caused by mutations in
mt-tRNA genes. Hence, they represent attractive lead molecules for
the development of compounds aimed at therapeutic applications
against syndromes associated with pathogenicmt-tRNAmutations.
Results
Pathological phenotype of m.8344A>G MTTKmutant
cybrids
First, we investigated the Cterm ability to rescue the pathological
phenotype of cybrid cells bearing a mutation in mt-tRNALys,
which is aminoacylated by class II LysRS. To this end, we ma-
nipulated m.8344A>G osteosarcoma-derived cybrids (kind gift
from Valeria Tiranti) using ethidium bromide (EtBr) to obtain dif-
ferent cell lines bearing either high or low levels of mutated mt-
DNA (see the Materials and Methods section). The assessment of
m.8344A>G mutation load was performed by quantitative pyro-
sequencing. The selected clones showed 34% (L-8344, low-mu-
tant percentage) and 86% (H-8344, high-mutant percentage)
m.8344A>G mutation loads, respectively. To investigate the
phenotype of mutant cell lines, cybrids were grown in glucose-
free medium supplemented with galactose (galactose medium),
a condition forcing cells to rely on the mt respiratory chain for
ATP synthesis. In this condition, cell growth of H-8344 cybrids
was severely impaired whereas L-8344 cybrids were indistin-
guishable fromWT cells (Supplementary Material, Fig. S1A), pro-
viding us with an isogenic control for further experiments.
Decreased viability of H-8344 cybrids was associated with an in-
crease in apoptosis and impaired respiratory chain activity, as
comparedwith isogenic L-8344 cybrids (Supplementary Material,
Fig. S1A–C). To evaluate the effect of them.8344A>Gmutation on
mt-tRNALys steady-state levels we performed high-resolution
northern blot analysis. We showed that high-mutation levels
are associatedwith a 50% decrease inmt-tRNALys steady-state le-
vels relative to the amount of 5SrRNA (Supplementary Material,
Fig. S1D).
The carboxy-terminal domain of human mt-LeuRS
is able to rescue the phenotype of m.8344A>G MTTK
mutant cybrids
We transiently expressed the Cterm in H-8344 and L-8344 cy-
brids. This resulted in increased cell viability of H-8344 cybrids
after 24 h incubation in galactose medium (up to 1.5-fold as com-
pared to mock transformants) and decreased apoptosis after 6 h
(up to 1.6-foldwhen comparedwithmock transformants) (Fig. 1A
and B). Moreover, Cterm transformants showed a significant in-
crease in oxygen consumptionwhen comparedwithmock trans-
formants (up to 1.4-fold increase) (Fig. 1C). Conversely, Cterm
overexpression did not affect viability of isogenic L-8344 cybrids
(Fig. 1A and C). For each experiment, we measured transfection
efficiency by quantitative real-time polymerase chain reaction
(PCR) (Fig. 1D).
Cterm-derived peptides are endowed with rescuing
ability towards both m.3243A>G MTTL1 and
m.8344A>G MTTKmutant cybrid phenotypes
The structural basis of the interaction between the Cterm of
human mt-LeuRS and the cognate tRNA can be inferred from
the analysis of the experimentally determined 3D structures of
LeuRS-tRNALeu complexes from the bacteria Thermus thermophilus
(14) and Escherichia coli (15) available from the Protein Data Bank
[PDB; (18)]. As shown in Figure 2, two pairs of β-strands in the car-
boxy-terminal domain of bacterial LeuRS (whose human homo-
logues were named β30_31 and β32_33 (16) comprise most of the
residues that are involved in contacts with the elbow region of
tRNALeu. Thus, we tested the hypothesis that the short peptides
from the human enzyme were responsible for the Cterm ability
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to interact with, and have rescuing activity towards, mutations
in human cognatemt-tRNALeu(UUR) and non-cognatemt-tRNALys.
The constructs designed for transfection experiments com-
prise: the mt-targeting sequence (MTS) of human COX8a gene, to
ensuremt localization; the nucleotide sequence coding for peptide
β30_31, β32_33 or Cterm (as a positive control) and a FLAG domain
(for more details see ‘Materials and Methods’ section).
We transiently overexpressed either β30_31 or β32_33 peptide
in cybrid lines, which were subsequently stressed by galactose
medium incubation. In these conditions, transformant cells
showed: (i) increased viability (up to 1.8- and 1.7-fold for
m.3243A>G and m.8344A>G cybrids, respectively, when com-
pared with their mock transformants); and (ii) decreased apop-
totic cell death (up to 1.6- and 2-fold for m.3243A>G and
m.8344A>G cybrids, respectively, when with to their mock trans-
formants) (Fig. 3A and B). Conversely, peptide overexpression had
no effect on the viability of WT and L-8344 cybrids (Supplemen-
tary Material, Fig. S2). To investigate whether increased cell
viability was actually related to improved mt bioenergetics, we
measured oxygen consumption rate in transfected cybrids. Pep-
tide β32_33 increased oxygen consumption in both m.3243A>G
and m.8344A>G cybrids, when compared with the respective
mock transformants; conversely, peptide β30_31 increased oxy-
gen consumption in m.8344A>G cybrids only (Fig. 3C).
We verified the transient over-expression of both Cterm and
Cterm peptides by real-time PCR for all experiments and by im-
munofluorescence for a subset of experiments (see the ‘Materials
and Methods’ section). Upon transfection, both peptide and
Cterm transformants showed increased mRNA expression levels
(Supplementary Material, Fig. S3) as well as intense cytoplasmic
granular stain with specific anti-FLAG antibodies which was
evident in about 50% of transfected cells (Fig. 4A). In addition,
mt localization following transient transfection was verified by
using a specific anti-FLAG antibody in combination with Mito-
tracker Red CMXRos (see Materials and Methods section). As
shown in Figure 4B, the peptide-specific immunofluorescence
pattern (green) perfectly superimposes the mt network (red).
We also investigatedwhether transfectionwith either peptide
affected the steady-state levels of mt-tRNA mutants. High-
resolution northern blot analysis was performed in WT and
m.3243A>G MTTL1 or m.8344A>G MTTK mutant cybrids transi-
ently transfected with peptide β30_31 or β32_33. Values were
normalized for 5S rRNA. Consistent with our previous report on
m.3243A>G MTTL1 mutant cybrids transfected with the Cterm
(9), transient overexpression of either peptide did not result in a
significant increase of the mutated mt-tRNALeu(UUR) or mt-
tRNALys steady-state levels (Supplementary Material, Fig.
S4). We performed additional experiments on m.3243A>G
MTTL1 mutant cybrids stably transfected with the Cterm, as
a ‘long term’ overexpression model. These resulted in a sig-
nificant increase in the steady-state levels of mutated mt-
tRNALeu(UUR) (Supplementary Material, Fig. S4), although
these changes were at the lower limits of detection for nor-
thern experiments.
Figure 1. The carboxy-terminal domain of human mt-LeuRS (Cterm) is able to rescue the phenotype of m.8344A>G MTTK mutant cybrids. (A) Viability of mock (M) and
Cterm (pCterm) transformants evaluated after 24 h incubation in galactosemedium. The number of viable cells in galactose is normalized to the number of viable cells in
glucose at the same time point. (B) Apoptotic cell death of M and pCterm evaluated after 6 h incubation in galactose medium. (C) A respiration rate measured in M and
pCterm. (D) Relative expression levels of Cterm in transformant cybridswith respect to 18S gene. Gene expression levels are normalized to the gene expression level of the
relativemock. L-8344 and H-8344: low- and high-percentagem.8344A>Gmutant cells. Results are themean ± SEM of at least triplicate transfection experiments. °P < 0.05,
°°P < 0.01 for H-8344 mock cells versus L-8344 mock cells. *P < 0.05, **P < 0.01 for transformants versus mock cells (T-test).
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Cterm-derived peptides directly interact with both
human mt-tRNALeu(UUR) m.3243A>G and mt-tRNALys
m.8344A>G mutants with high affinity in vitro
The ability of peptides β30_31 and β32_33 to interact with theWT
andmutated tRNAs under investigationwas evaluated by surface
plasmon resonance (SPR) experiments. Thesewere carried out by
immobilizing N-biotinylated peptides onto BioCap sensorchips
and adding human mt-tRNALeu(UUR) (WT or m.3243A>G mutant),
or human mt-tRNALys (WT or m.8344A>G mutant) as analytes.
Figure 5 shows the sensorgrams of each of the eight evaluated in-
teractions (A–D), a logarithmic plot of all experiments with pep-
tides β30_31 (E) and β32_33 (F), and a table with the KD values of
each peptide for each tRNA, obtained from Scatchard analysis
of all the experiments (G).
Both peptides interact directly and with high affinity with all
four tRNAs, although the strength of the interactions differs sub-
stantially. Unsurprisingly, the most efficient interactions are
with the cognate human mt-tRNALeu(UUR) forms. Peptide β30_31
shows KD = 34 and 44 µm with WT and m.3243A>G mutant, re-
spectively, while peptide β32_33 interacts with even higher affin-
ity with both forms (KD = 1.0 and 1.6 µwithWT andm.3243A>G
mutant). Remarkably, these values are very similar to the affinity
of thewhole Cterm formt-tRNALeu(UUR) [i.e. 0.6 µ; (9)], indicating
that peptide β32_33 comprises most of the Cterm residues
required for cognate mt-tRNA recognition. Interestingly, peptide
β32_33 has higher affinity than β30_31 towards non-cognate
human mt-tRNALys as well (Fig. 5). These results suggest that
peptides β30_31 and β32_33 might be able to recognize general
tRNA features and, therefore, bind additional non-cognate
tRNA molecules.
Cterm-derived peptides compensate structure
and thermal stability impairments of both human
mt-tRNA mutants in vitro
Thermal denaturation (TD) experiments were carried out to elu-
cidatewhether, and towhat extent, the interactionwith peptides
β30_31 and β32_33 reverts the structure and thermal stability al-
terations that occur in human mt-tRNALeu(UUR) and mt-tRNALys
as a consequence of the m.3243A>G and m.8344A>G mutations,
respectively. To this end, tRNAs were synthesized as molecular
beacons (MB-tRNAs) with chemical groups able to emit and
quench fluorescence at the 5′ and 3′ ends, respectively.
In all experiments, low fluorescencewas observed at low tem-
perature, due to the vicinity of the 6-carboxyfluorescein (FAM)
fluorophore andDABCYL quencher (at 5′ and 3′ end, respectively),
and high fluorescence upon thermal melting, due to decreased
fluorescence quenching caused by tRNA unfolding. Figure 6A–H
Figure 2. Structural basis of the interaction between peptides derived from LeuRS and cognate tRNALeu. (A) A 3D structure of LeuRS-tRNALeu complex from T. thermophilus
(14). The structural domains of LeuRS are represented as ribbon and coloured as follows: catalytic, leucine-specific, editing and anticodon-binding domains are yellow,
pink, cyan and lilac, respectively; peptides β30_31 and β32_33 are blue andmagenta, respectively, and the rest of the carboxy-terminal domain is green. tRNALeu is coloured
orange and tRNA bases are shown as sticks. The phosphorous atoms of nucleotides 14 and 55 at the beginning of the D- and T-loop, respectively, corresponding to tRNA
regions where pathogenic point mutations occur in MELAS (m.3243A>G) and MERRF (m.8344A>G) diseases, are shown as red spheres. (B) Zoom-in of the interaction
between peptides β30_31 and β32_33, within the carboxy-terminal domain of LeuRS, and the ‘elbow’ region of tRNALeu, where the two branches of the ‘L’-shaped
tertiary structure join to each other. Colour-coding is as in panel A. (C) Multiple sequence alignment of the carboxy-terminal domains of LeuRS from T. thermophilus
(Tt) and E. coli (Ec), and of mt-LeuRS from Saccharomyces cerevisiae (Sc) and Homo sapiens (Hs). The secondary structure elements of Tt-LeuRS are reported above the
alignment: α, alpha-helix; β, beta-strand. Residues in contact with tRNALeu in the experimentally determined 3D structures of Tt-LeuRS (14) and Ec-LeuRS (15) have a
black background. Residues belonging to peptides β30_31 and β32_33 of human mt-LeuRS have a blue and magenta background, respectively.
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shows the results of thermal shift assays (average of three experi-
ments) performed on human MB-mt-tRNALeu(UUR) WT and
m.3243A>G mutant (A–D), and MB-mt-tRNALys WT and
m.8344A>G mutant (E–H), in the presence of different concentra-
tions of peptide β30_31 or β32_33. Figure 6I reports the values of
MB-tRNAs melting temperature (Tm) and percentage of folding
at 37% (%Folded37) calculated for each series of experiments.
The thermal and structural stability of MB-mt-tRNALeu(UUR)
m.3243A>Gmutant are lower than theWT in the absence of pep-
tides (Tm= 48°C for both forms but%Folded37 = 66% for themutant
and 82% for the WT) and increase significantly upon addition of
peptide β30_31 and β32_33 up to 2 µ. Consistent with the results
of tRNA-binding affinity, peptide β32_33 has the highest stabiliza-
tion effect (Tm increases by 4°C versus 1°C and %Folded37 in-
creases by 8 versus 5%). As expected, WT MB-mt-tRNALeu(UUR)
undergoes only small changes in thermal and structural stability
in the presence of peptide β30_31 up to 3 µ and β32_33 up to 2 µ
(see Fig. 6). Intriguingly, the structures ofMB-mt-tRNALys (WTand
m.8344A>G mutant) are slightly stabilized by peptide β30_31 but
not by the addition of peptide β32_33.
Figure 3. Short peptides derived from the Cterm improve cell viability and energetic proficiency of both m.3243A>G MTTL1 and m.8344A>G MTTK mutant cybrids.
(A) Viability of mock, Cterm, β30_31 and β32_33 transformant cybrids (M, pCterm, pβ30_31 and pβ32_33) bearing either the m.3243A>G point mutation (left panel) or
high levels of the m.8344A>G point mutation (right panel), evaluated after 24 h incubation in galactose medium. The number of viable cells in galactose medium is
normalized to the number of viable cells in glucose at the same time point. (B). Apoptotic cell death of m.3243A>G (left panel) or H-8344 (right panel) M, pCterm,
pβ30_31 and pβ32_33 evaluated after 6–12 h incubation in galactose medium. (C) The rate of oxygen consumption of m.3243A>G (left panel) or H-8344 (right panel).
WT, wild-type; 3243, m.3243A>G mutant cells; L-8344 and H-8344, low- and high-m.8344A>G mutation load. Data are normalized to the value obtained in mock
mutant cells. Results are the mean ± SEM of at least triplicate transfection experiments. #P < 0.05, ###P < 0.001 for 3243 mock mutant cells versus WT mock cells;
°P < 0.05, °°P < 0.01, °°°P < 0.001 for H-8344 mock cells versus L-8344 mock cells for H-8344 mock cells; *P < 0.05, **P < 0.01, ***P < 0.001 for transformants versus mock cells
(T-test).
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Figure 4. The Cterm- and short-peptide derivatives are over-expressed and colocalize to mitochondria. (A) Representative images showing the over-expression of MTS-
Cterm-FLAG, MTS-β30_31-FLAG and MTS-β32_33-FLAG constructs in transformant cybrids. Immunofluorescence shows M, pCterm, pβ30_31 and pβ32_33 stained with a
specific anti FLAG antibody. Nuclei are stained with 4′,6-diamidino-2-phenylindole (scale bar: 20 µm). (B) Stain of mock, Cterm, β30_31 and β32_33 transformants (M,
pCterm, pβ30_31 and pβ32_33) showing colocalization of the antibody against the FLAG and the Mitotracker Red CMXRos. Overlap is shown in yellow. WT cells were
examined and imaged with an Olympus IX50 fluorescence microscope (scale bar: 20 µm).
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Figure 5. Short peptides derived fromtheCterm interact directly andwithhigh affinitywith bothhumanmt-tRNALeu(UUR)m.3243A>G andmt-tRNALysm.8344A>Gmutants
in vitro. (A–D) Sensorgrams of the interaction between N-biotinylated β30_31 (A and C) or β32_33 (B and D) peptide, immobilized on BioCap sensorchips, with humanWT
(left panels) of mutant (right panels) mt-tRNAs. (A). mt-tRNALeu(UUR) (left) and mt-tRNALeu(UUR) m.3243A>G mutant (right); tRNA concentrations: 1.5; 3.0; 6.0; 12; 24 and
48 µ. (B) mt-tRNALeu(UUR) (left; concentrations = 0.8; 1.5; 3.0; 6.0 and 12 µ) and mt-tRNALeu(UUR) m.3243A>G mutant (right; concentrations: as in (A). (C) mt-tRNALys
(left) and mt-tRNALys 8344A>G mutant (right); tRNA concentrations: 0.75; 1.5; 3.0; 6.0; 12; 24 and 48 µ at 0–20; 21–40; 41–60; 61–80; 81–100; 101–120 and 121–130 s,
respectively. (D) mt-tRNALys (left) and mt-tRNALys m.8344A>G mutant (right); tRNA concentrations: 0.37 µm; 0.75 µ; 1.5 µ; 3.0 µ; 6.0 µ; 12 µ; 24 µ at the same
time points as in (C). (E and F) Logarithmic plot of the interaction of N-biotinylated β30_31 (E) and β32_33 (F) peptide with human WT mt-tRNALeu(UUR) (white circle),
mt-tRNALeu(UUR) m.3243A>G mutant (black circle), human WT mt-tRNALys (white square) and mt-tRNALys m.8344A>G mutant (black square). The maximal response is
plotted versus the logarithm of tRNA concentration. (G) KD values of the interactions between peptides and tRNAs.
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All TD experiments were highly reproducible. Melting curves
measured in the same experimental conditions from different
samples are entirely superimposable, with standard deviations
for Tm values below 1°C for each measurement.
Supplementary Material, Figure S5 section shows gel electro-
phoresis of 1 µmt-tRNALeu(UUR) m.3243A>G samples incubated
in 20 m HEPES (pH 7.4), 150 m NaCl, 1 m MgCl2 and 0.1 m
Spermine (Spm) for 15′ in the presence of β30_31 or β32_33 pep-
tides. The interaction with 10 µ peptides decreases by ∼7–10%
the amount of mt-tRNALeu(UUR) m.3243A>G mutant in the dimer
form (upper band), first reported by Wittenhagen and Kelley
(19), whereas in the same conditions WT mt-tRNALeu(UUR) is
fully monomeric.
Discussion
In the present study, we expand recent results previously re-
ported by our group and others about the ability of human mt-
LeuRS Cterm to interact with both cognate and non-cognate
mt-tRNAs, and rescue pathological phenotypes arising from
mt-tRNA mutations in human cells (9,10). While the Cterm had
been shown to interact with a number of non-cognate mt-
tRNAs aminoacylated by both class I and II aminoacyl-tRNA
synthetases (aaRSs) (10), its rescuing ability had been
demonstrated only towards mt-tRNAs aminoacylated by aaRSs
belonging, like LeuRS, to class Ia (9). Since aaRSs belonging to
the same class and subclass have higher structure and sequence
similarity to one another than to other aaRSs, whether the thera-
peutic properties of the Cterm could be extended tomutations in
mt-tRNAs aminoacylated by aaRSs other than those in class Ia
remained an open question.
Here, we show that, remarkably, the Cterm is able to amelior-
ate the phenotype of cybrid cells carrying the m.8344A>G muta-
tion in mt-tRNALys, which has the following features: (i) the
cognate LysRS belongs to class II and thus is not evolutionarily
related to class I enzymes; (ii) it is one of the most prevalent
among disease-causing mt-tRNAmutations; (iii) it is responsible
for a severe syndrome (MERRF). Together with recent observa-
tions in yeast (16,17), these results strongly support the hypoth-
esis that the Cterm may rescue defects due to mutations in a
number of additional mt-tRNAs aminoacylated by aaRSs belong-
ing to both classes. This makes the Cterm a promising candidate
as ‘universal suppressor’ for mt-tRNA mutation-associated
diseases.
Importantly, we demonstrate here that not only LeuRS
C-terminal domain but also two short peptides derived from it,
β30_31 and β32_33, are endowed with rescuing ability towards
two mutations: m.3243A>G in mt-tRNALeu(UUR) and m.8344A>G
Figure 6. Short peptides derived fromtheCtermrestore thermal stabilityand structure ofmutatedmt-tRNALeu(UUR). (A–H) Thermal shift assays (average of threeexperiments)
performed on humanWTmt-tRNALeu(UUR) (A and B),mt-tRNALeu(UUR)m.3243A>G (C andD),WTmt-tRNALys (E and F) andmt-tRNALysm.8344A>G (G andH) in the presence of
1 mMg2+, 0.1 m spermine (Spm) and different concentrations of β30_31 (A, C, E and G) or β32_33 (B, D, F and H) peptide (A–D: black, 0 µ; blue, 0.2 µ, green, 0.5 µ; red,
2 µ; (E–H): black, 0 µ; blue, 0.4 µ; green, 2 µ). (I) Table showing the maximum observed variation in Tm and %Folded37 (see the ‘Materials and Methods’ section) upon
treatment with peptides.
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in mt-tRNALys. The ability of both peptides to rescue pathological
phenotypes due to mutations in a number of mt-tRNAs, which
are aminoacylated by aaRSs belonging to different classes and
subclasses, has been recently suggested in yeast (17). Our results
on the activities of peptides β30_31 and β32_33, together with the
overall LeuRS sequence conservation from eukaryote mitochon-
dria to bacterial cells indicate that, in spite of the evolutionary
distance and different cellular compartment, the modality of
tRNA recognition and regions involved in tRNA binding are large-
ly conserved.
The overall rescuing activity of peptides β30_31 and β32_33 is
manifested by increased cell viability and decreased apoptotic
cell death, as is the case with the Cterm (9). Intriguingly, while
peptide β32_33 restores oxygen consumption of both mutant
cybrids, upon transfection with peptide β30_31 this effect is ob-
served only in m.8344A>G cybrids, suggesting a different effect
of this peptide on the respiratory chain function affected by
either mutation.
Despite the significant increase in cell viability, we did not
detect an increase of either mutant mt-tRNALeu(UUR) or mt-
tRNALys steady-state levels upon transient overexpression of ei-
ther peptide β30_31 or β32_33. These results are in line with our
previous observations on m.3243A>G cybrids transiently trans-
fected with the Cterm (9) and suggest that, in agreement with
our hypothesis of a chaperonic mechanism of action, the effect
of ourmolecules ismainly to improve the function of themutant
mt-tRNAs, rather than preventing them fromdegradation. On the
other hand, we observed a slight, albeit significant increase of
mutant mt-tRNALeu(UUR) steady-state levels after stable transfec-
tion of m.3243A>G cybrids with the Cterm. Thus, on a longer
timescale an effect on mutant mt-tRNA steady state levels can
be highlighted, which may contribute to the rescuing activity.
The results of our in vitro experiments contribute to elucidate
the molecular basis of the rescuing activity of peptides β30_31
and β32_33 and support the hypothesis that theyact asmolecular
chaperones, as previously proposed for the Cterm. In fact, in spite
of their small size, the two peptideswere able to bind directly and
with high affinity to allWTandmutantmt-tRNAs investigated in
this work. These results suggest that peptide-tRNA interactions
are mediated by structural features shared by tRNA molecules,
consistentwith the rationale behind peptide design. Accordingly,
both peptides bind WT mt-tRNAs with higher affinity than their
mutant counterparts, the structure of which is affected by the
presence of the mutation. Peptide β32_33 showed a significantly
higher binding affinity than peptide β30_31 towards each and all
of the investigated tRNA forms, indicating that it is a better can-
didate for future therapeutic applications.
To investigate the effects of peptide binding on the mt-tRNA
structure and stability, we performed thermal melting experi-
ments on tRNAs modified to act as MB-tRNAs. These experi-
ments highlighted that the m.3243A>G mutation induces a
thermal and structural destabilization of mt-tRNALeu(UUR), both
of which are reversed by association with peptide β32_33 and,
to a lesser extent, β30_31. These results support the hypothesis
that the two peptides act like molecular chaperones, by stabiliz-
ing a mt-tRNALeu(UUR) conformation suitable to establish interac-
tions with partner molecules (e.g. aaRSs, elongation factors,
ribosome, mRNAs etc.) that are required to enact tRNA function.
In addition, themutation-dependent dimerization ofmt-tRNALeu
(UUR) m.3243A>G, which may contribute to impairment of the
tRNA function, is substantially decreased by the interaction with
peptides β30_31 and β32_33 (SupplementaryMaterial, Fig. S5). Con-
versely,we could not detect a significant increase in either thermal
stability or folding of the mt-tRNALys m.8344A>G mutant, despite
the ability of both peptides to directly interact with both WT and
mutant tRNALys with high affinity. This result may be ascribed
to the absence of post-transcriptional modifications in the
in vitro synthesized WT and mutant mt-tRNALys used in our ex-
periment, since editing has been proposed to play an important
role in the stabilization of a canonical two-dimensional and 3D
mt-tRNALys structure (20,21). Alternatively, in the case of the
mt-tRNALys mutant the rescuing effect of the peptides may
bemediated by a non-chaperonic mechanism, consisting, for ex-
ample, in the protection from degradation. Although we cannot
exclude that the effect of β32_33 peptide on mt-tRNALys stability
depends on peptide binding to regions different from those re-
cognized in ‘cognate’ mt-tRNALeu(UUR), the ability of the β32_33
peptide to rescue defects due to mutations in a large panel of
mt-tRNA mutants previously demonstrated in yeast (17) sup-
ports the hypothesis that common structural features of tRNA
molecules are at least partially involved in the interaction.
In conclusion, we provide evidence that small peptides
derived from themt-LeuRS Cterm can be effective tools to rescue
cellular defects caused by mutations in mt-tRNAs. As a conse-
quence, these peptides represent an important advance in the
quest for therapeutic agents against diseases caused by muta-
tions in mt-tRNAs. The whole Cterm is amenable to gene ther-
apy-based approaches [see for example (22,23)], whilse small
peptides could be more directly administered, possibly aided by
suitable carriermolecules and/ormitochondria-targeting agents.
Additionally, small peptidesmay serve as a basis for the develop-
ment of non-peptide synthetic compounds, particularly if the
rescuing activity can bemapped to even smaller peptide regions.
Strikingly, the ability of the peptide to rescue defects due to
mutations in ‘non-cognate’ in addition to ‘cognate’ mt-tRNAs
suggests that they may be used to develop wide-spectrum thera-
peutics towards mt-tRNA mutation-associated diseases.
Materials and Methods
Cybrid cell lines
For this study, we used previously established osteosarcoma-de-
rived (143B.TK−) cybrid cell lines from patients (24) and controls
[(25); generous gift from Dr Valeria Tiranti and Dr Valerio Carelli]
(SupplementaryMaterial, Table S1). Them.8344A>G cybridswere
established in Valeria Tiranti’s laboratory as previously described
(26).We thenmanipulated the ratio ofmutant andWTmt-DNAof
the m.8344A>G cybrids using EtBr. Cybrid cells were maintained
in glucose medium supplemented with 20 ng/ml of EtBr for 10
days as previously described (27) and replated to repopulate
mitochondria at low density in glucose medium. Individual cell
clones (∼50) were isolated 10–20 days later using glass cylinders
and tested for the mutation load. For the present study, we se-
lected two clones, showing high (86%) and low (34%) levels of
m.8344A>G mutation, respectively.
Assessment of m.8344 A>G mutation load
Accurate m.8344A>G heteroplasmy levels were obtained by
quantitative pyrosequencing using a Pyromark Q24 platform. The
PyroMark assay design software v2.0 (Qiagen, Hilden, Germany)
and the current mtDNA reference sequence (Genbank accession
number: NC_012920.1) were used to designmutation-specific pyro-
sequencing primer trios [5′biotinylated forward: m. 8240–8264; re-
verse: m. 8364–8387 and reverse pyrosequencing primer: m.8348–
8367 (IDT, Coralville, IA, USA)]. The allele quantification application
of the proprietary Q24 software was used to calculate mtDNA het-
eroplasmy levels using standard parameters.
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Cell culture
Cybrid cells were cultured in Dulbecco’s modified Eagle’s me-
dium (DMEM), supplementedwith 4.5 g/l d-glucose, 10% fetal bo-
vine serum (FBS), 2 m l-glutamine, 50 µg/ml uridine, 100 U/ml
penicillin and 100 mg/ml streptomycin (referred to as glucose
medium) in a humidified atmosphere of 95% air and 5% CO2 at
37°C. For a subset of experiments cybrids were grown in glu-
cose-free DMEM, supplemented with 5 m galactose, 110 mg/ml
sodium pyruvate and 10% FBS (referred as galactose medium).
Bioinformatics analysis
Structure visualization and analysis were performed using
PyMol (http://www.pymol.org/). Cterm residues interacting with
tRNALeu in experimentally determined 3D structures (14,15)
were calculated using the FACE2FACE server developed by the
authors (http://apps.ibpm.cnr.it/f2f/index). The multiple se-
quence alignment shown in Figure 2C was obtained by merging
the alignments of human and yeast mt-LeuRS to LeuRS from
T. thermophilus and E. coli obtained using Phyre2 (28).
Plasmid construction
Cybrid cells were transiently transfected with either the C-ter-
minal region of human mt-LeuRS (named pCterm) or the short
peptides derived from it (named pβ30_31 and pβ32_33) cloned
into pcDNA3.2-TOPO vector (Invitrogen™, Life Technologies Ita-
lia, MB, Italy). The cDNA fragments (listed in Supplementary Ma-
terial, Table S2) were fused at 5′with themitochondrial-targeting
sequence (MTS) derived from human COX8 gene (29) and at 3′
with the FLAG sequence (5′-GATTACAAGGATGACGACGATAAG-
3′). Both the MTS and the FLAG sequences were separated from
the peptide sequence by a 5-residue linker (GGSGG).
Transient and stable transfections
Cybrids were plated in 60 mm dishes, incubated in glucose me-
dium for 24 h, and then transfected with 2.5 µg of the full or
empty vector (mock) by using LIPOFECTINE 3000 (Life Technolo-
gies Italia), according to the manufacturer’s protocol. Stable
clones were selected andmaintained in glucosemedium supple-
mented with G418 (300 µg/ml). Prior to testing the effect of our
constructs, we verified that the mutation load of m.3243A>G
and m.8344A>G mutant cybrids did not change upon transfec-
tion (Supplementary Material, Fig. S6). To assessm.3243A>Gmu-
tation load we used the assay previously described by McDonnel
et al. (30). Briefly, WT 154 base-pairs (bps) PCR products amplified
with forward (5′-TATACCCACACCCACCCAA-3′) and reverse
(5′-GCGATTAGAATGGGTACAAT −3′) primers contain a single
HaeIII restriction site, which cleaves the amplicons into two frag-
ments of 117 and 37 bps. The m.3243A>G mutation introduces a
second HaeIII recognition site that cuts the 117 bps fragment into
two smaller fragments of 72 and 45 bps. To assess m.8344A>G
mutation load, we used the assay previously described by Lars-
son et al. (31). Briefly, WT 230 bps PCR products, amplified with
forward (5′-CTACGGTCAATGCTCTGAAA-3′) and reverse (5′-ATA
CGGTAGTATTTAGTTGGGGCATTTCACTGTAAAGCCGTGTTGG-3′)
mismatch primers, do not contain any BglI restriction site. The
m.8344A>G mutation introduces a BglI recognition site that
cuts the 230 bps fragment into two smaller fragments of 184
and 46 bps.
Restriction fragments were separated and identified using the
Agilent 2100 bioanalyzer instrument with the 1000 Lab Chip kit
(Supplementary Material, Fig. S6).
Evaluation of transient transfection efficiency
by real-time PCR
About 24 h after transfection total RNA was isolated, measured
and reverse-transcribed to cDNA as previously described (9). To
assess the relative expression of MTS-Cterm-FLAGwe used Taq-
Man probe chemistry by means of custom FAM-labelled TaqMan
MGB probe (Applied BiosystemsWarrington, UK; Supplementary
Material, Table S3), according to themanufacturer’s instructions.
In all samples, the relative expression of the target genewas eval-
uatedwith respect to the average of controls (mock sample) using
the comparative threshold cycle (ΔCt) method. All values were
normalized for the housekeeper 18S ribosomal RNA (18S) using
inventoried FAM-labelled TaqMan MGB probes (Supplementary
Material, Table S3). Due to the shortness of Cterm-peptides the
primers of the real-time PCR assays were design to anneal, re-
spectively, with theMTS and the FLAG sequence (Supplementary
Material, Table S3). These assays prevented the normalization of
over-expressed β30_31 and β32_33 relative to the endogenous
levels of mt-LeuRS in the mock.
Evaluation of constructs expression levels
by immunofluorescence
About 24 h after transfection cells were fixed with 4% formalde-
hyde freshly prepared from paraformaldehyde in phosphate
buffered saline (PBS) (pH 7.4) with 0.1% Triton X-100. Mouse
monoclonal anti-FLAG (Sigma, Saint Louis, MO, USA) was used
as primary antibody and visualized using secondary fluorescein
isothiocyanate-conjugated antibody (Jackson Laboratories, Bar
Harbor, ME, USA). Cells were examined and imaged with an
Olympus IX50 Fluorescence microscope.
Mt localization of constructs
About 24 h after transfection cells were incubated with 100 nm
Mitotracker red CMXRos (Life Technologies Italia) for 20 min at
37°C and then fixed with 4% formaldehyde freshly prepared
from paraformaldehyde in PBS (pH 7.4) for 15 min at 37°C. Subse-
quently cells were incubated with mouse monoclonal anti-FLAG
(Sigma) and visualized by mean of secondary Alexa fluor goat
anti-mouse 488 (Life Technologies Italia).
Cell proliferation assay
To test growth capability, transformed cells were maintained in
glucose medium for 24 h and then harvested and seeded at
30 × 104 in 60 mm dishes in glucose or galactose. Cell viability
was measured by the Trypan blue dye exclusion assay. Cells
were harvested after 24 h with 0.25% trypsin and 0.2% ethylene-
diaminetetraacetic acid, washed, suspended in PBS in the pres-
ence of Trypan blue solution (Sigma) at 1:1 ratio, and counted
using a haemocytometer. The number of viable cells in galactose
medium was expressed as a percentage of the number of cells in
glucose medium.
Rate of apoptosis by flow cytometer
To test the rate of apoptosis transformed cells were maintained
in glucose medium for 24 h and then harvested and seeded at
0.5–1 × 106 in glucose or galactose for 6–24 h. Cells were washed
and harvested in binding buffer 1× (BD Biosciences, Franklin
Lakes, NJ, USA) by scraper to minimize potentially high annexin
V background levels in adherent cells. Transfected cells were
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stained with APC-conjugated annexin V (BD Biosciences) and
analysed on a FACS-Calibur flow cytometer (BD Biosciences) (32).
Respirometry assay
Oxygen consumption rate (OCR) of transfected cybrids was eval-
uated with Clark type oxygen electrode (Hansatech Instruments,
Norfolk UK). After transfection control and mutant cybrids were
maintained in glucosemedium for 48 h, then OCRwasmeasured
in intact cells (3 × 106) in 1 ml DMEM lacking glucose supplemen-
ted with 10% sodium pyruvate, as previously described (33).
High-resolution northern
To determine mt-tRNALeu(UUR) and mt-tRNALys steady-state le-
vels cybrids were maintained in glucose medium for 12 h and
then collected for RNA extraction. Total RNA was obtained
using Trizol reagent (Life Technologies, Paisley, UK). RNA (2 µg)
was electrophoresed through 13% denaturing polyacrylamide
gel, electroblotted onto Hybond N+ membrane (GE Healthcare
Life Sciences, Little Chalfont, UK) in 0.25× TBE and immobilized
by ultraviolet cross-linking. Hybridization with radiolabelled
probes was performed as previously described (34). Primers for
generating the mt-tRNALeu(UUR) and mt-tRNALys probes were
L3200 (positions 3200–3219; GenBank accession number:
NC_012920.1 for human mtDNA) and H3353 (positions 3353–
3334), and L8246 (positions 8246–8266) and H8390 (positions
8390–8371), respectively. Steady-state mt-tRNA levels were nor-
malized to that of 5S rRNA (RN5S17; GenBank accession number:
NR_023379.1); primers for generating the 5S probe were F1 (posi-
tions 1–23) and R121 (positions 121–101).
SPR experiments
SPR experiments were carried out with a SensiQ Pioneer appar-
atus. N-biotinylated β30_31 and β32_33 peptides (see Fig. 2)
were synthesized by Biomatik (purity > 90%). Streptavidin-coated
BioCap sensorchipswere chemically activated bya 35 µl injection
of 10 m NaOH at 10 µl/min flow rate. N-biotinylated peptides
were immobilized via interaction with the streptavidin surface
of the chips. This procedure ensured directional immobilization
of the peptides. The amount of immobilized peptides was de-
tected by mass concentration-dependent changes in the refract-
ive index on the sensor chip surface, and corresponded to ∼50
resonance units (RU).
Samples of human WT mt-tRNALeu(UUR), mt-tRNALeu(UUR)
m.3243A>G, WT mt-tRNALys and mt-tRNALys m.8344A>G, were
synthesized and modified by Trilink Biotechnologies. All tRNA
samples were dissolved in sterile HEPES 20 m pH 7.4, NaCl
150 m, 1 mMgCl2, heated to 80°C for 5 min and slowly cooled
down to room temperature to allow renaturation.
The tRNA-binding experiments were carried out at 298 K in
degassed 20 m HEPES at pH 7.4, 0.15 M NaCl, 1 m MgCl2 and
0.005% surfactant P-20 (HBS-MP buffer GE Healthcare Life
Sciences, Milan, Italy). Sample injections were performed for ex-
periments on both mt-tRNALeu(UUR) WT and m.3243A>G mutant
for 100 s at 30 µl/min. Concentrations of (i) mt-tRNALeu(UUR) WT
and m.3243A>G mutant with β30_31 peptide: 1.5; 3.0; 6.0; 12; 24
and 48 µ; (ii) mt-tRNALeu(UUR) WT with β32_33 peptide: 0.8; 1.5;
3.0; 6.0 and 12 µ and (iii) mt-tRNALeu(UUR) m.3243A>G mutant
with β32_33 peptide: 1.5; 3.0; 6.0; 12 and 24 µ. For both human
mt-tRNALys WT and m.8344A>G mutant, injections were carried
out as follows. tRNAs were automatically diluted in HBS-MP and
injected by seven serial doubling steps (step contact time = 20 s,
nominal flow rate = 100 µl/min). At the following time points: (i)
0–20 s; (ii) 21–40 s; (iii) 41–60 s; (iv) 61–80 s; (v) 81–100 s; (vi) 101–
120 s and (vii) 121–130 s, tRNA concentrations were: (i) 0.75; (ii)
1.5; (iii) 3.0; (vi) 6.0; (v) 12 µ; (vi) 24 µ and (vii) 48 µwithpeptide
β30_31 and (i) 0.37; (ii) 0.75; (iii) 1.5; (iv) 3.0; (v) 6.0; (vi) 12 µ; (vii)
24 µwith peptide β32_33. The increase in RU relative to baseline
indicates complex formationbetween the immobilizedN-biotiny-
latedpeptide and tRNA. Theplateau region represents the steady-
state phase of the interaction. The decrease in RU (after 100 s for
WT and mutant mt-tRNALeu(UUR) and 130 s for WT and mutant
mt-tRNALys) indicates tRNA dissociation from the immobilized
peptide after buffer injection. A response change of 1000 RU typ-
ically corresponds to 1 ng/mm2 change in analyte concentration
on the sensor chip.
As a negative control, sensor chips were treated as described
above in the absence of immobilizedN-biotinylated peptides. Va-
lues of the plateau signal at steady-state (Req) were calculated
from kinetic evaluation of the sensorgrams using the Qdat 4.0
programme. The equilibrium constant of ligand–analyte inter-
action was evaluated by Scatchard analysis of the dependence
of Req on analyte concentration.
TD experiments on tRNA-MBs
Samples of human WT mt-tRNALeu(UUR), mt-tRNALeu(UUR)
m.3243A>G, WT mt-tRNALys and mt-tRNALys m.8344A>G were
synthesized by Trilink Biotechnologies. All tRNAs used for TD ex-
periments were synthesized as MB-tRNAs by using a 3′-DABCYL
support for tRNA synthesis, and 5′ FAM modification was added
using phosphoramidite chemistry. Dual polyacrylamide gel elec-
trophoresis/high-pressure (or high-performance) liquid chroma-
tography purification was performed for all samples, followed by
a desalting step and subsequent lyophilization of the final com-
pound. For all tested samples, purity was >95%. β30_31 and
β32_33 peptides were synthesized by Biomatik (purity > 90%).
TD experiments were performed with a Mx3000P Real-Time
PCR System (Stratagene, La Jolla, CA, USA) in PCR-96-microplates,
using 25 µl sample volume, 0.14 µMB-tRNAs in 20mHEPES pH
7.4 + 150 mNaCl + 1 mMgCl2 + 0.1 m spermine (Spm), and dif-
ferent concentrations of β30_31 or β32_33 peptide. At least two ex-
periments were performed for each condition, and triplicate
sampleswere usedwithin the same experiment. Sample tempera-
ture was increased from 25 to 90°C at 0.5°C/min rate. Fluorescence
wasmeasured at each temperature step (0.5°C) using FAM filter set
(excitation: 492 nm, emission: 516 nm). As negative controls we
used samplewellswith 20 mHEPESpH7.4 + 150mNaCl + 1 m
MgCl2 + 0.1 m spermine alone or in the presence of either MB-
tRNA or different concentration of β30_31 or β32_33 peptide.
Normalized fluorescence values of the traces [relative
fluorescence (F)] were obtained by dividing the fluorescence
intensity of each sample by the maximum fluorescence of the
same trace. For each temperature (T), the differential fluorescence
(dF) value of each trace was obtained as follows: dF = F(T + 0.5°C)
−F(T). For each experimental condition melting temperature
ðTmeqÞ values were calculated by determining the temperature of
maximal dF, and the percentage of folded sample at 37°C (%
Folded37) was calculated as follows: %Folded37 = 100 × [F(37°C)−
Fmin]/[1− Fmin], where Fmin is the minimum value of F for the
group of experiments.
Gel electrophoresis
Gel electrophoresis of 1 µmmt-tRNALeu(UUR)m.3243A>G samples,
incubated in 20 m HEPES (pH 7.4), 150 m NaCl, 1 m MgCl2
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and 0.1 m Spm for 15′ in the presence of different amounts of
β30_31 or β32_33 peptides was carried out in 12% native electro-
phoresis gel, and stained using SYBR Green. Dimerization per-
centage in each lane was calculated using the Fiji suite.
Statistical analysis
All data are expressed as mean ± SEM. Data were analysed by
standard paired t-test procedures. The significance was consid-
ered at P < 0.05. Numerical estimates were obtained with the
Graphpad InStat 3 version (Graphpad, Inc., San Diego, CA, USA).
Supplementary Material
Supplementary Material is available at HMG online.
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